# VeraMorph

Source: https://onco.cc/companies/veramorph/  
OnCo record `veramorph` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VeraMorph is developing VER001, a tablet version of fulvestrant, a hormone-blocking breast cancer drug now given as a monthly injection. It is in laboratory testing.

## Summary

VeraMorph has an oral drug delivery platform, DPOD, for poorly soluble drugs, and is using it to make oral versions of approved medicines. Its lead product VER001 is an oral formulation of fulvestrant, the selective oestrogen receptor degrader given as a monthly intramuscular injection, for oestrogen receptor-positive metastatic breast cancer. In fiscal year 2026 NCI awarded it USD 935,236 under SBIR award 4R44CA306533-02 for preclinical validation of oral fulvestrant.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: VeraMorph, LLC; VERAMORPH, LLC
- HQ: Norwood, MA
- Type: biotech
- Website: https://www.veramorph.com/

## Notes

- The company's claims that its oral fulvestrant is effective are its own and preclinical. Read on veramorph.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://www.veramorph.com/
- VeraMorph: product portfolio: https://www.veramorph.com/portfolio
- NIH RePORTER: SBIR award 4R44CA306533-02: https://reporter.nih.gov/project-details/11457452

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Oral SERDs](https://onco.cc/technologies/oral-serds/)
- targets: [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/)
- drugs: [VER001](https://onco.cc/drugs/ver001/)

---
JSON: https://onco.cc/api/v1/entities/veramorph.json